Karyopharm Execs Hit With Investor Suit Over Cancer Drug
A number of Karyopharm Therapeutics Inc.'s board members and executives are targeted in a shareholder's derivative lawsuit filed Monday in Massachusetts federal court accusing them of having a hand in misleading...To view the full article, register now.
Already a subscriber? Click here to view full article